Transforming cancer treatment: The potential of nanonutraceuticals

IF 5.3 2区医学 Q1 PHARMACOLOGY & PHARMACY

International Journal of Pharmaceutics Pub Date : 2024-11-07 DOI:10.1016/j.ijpharm.2024.124919

Girish Kumar , Tarun Virmani , Vaishnavi Chhabra , Reshu Virmani , Kamla Pathak , Md Sayeed Akhtar , Mulazim Hussain Asim , Shumaila Arshad , Farzana Siddique , Pedro Fonte

{"title":"Transforming cancer treatment: The potential of nanonutraceuticals","authors":"Girish Kumar , Tarun Virmani , Vaishnavi Chhabra , Reshu Virmani , Kamla Pathak , Md Sayeed Akhtar , Mulazim Hussain Asim , Shumaila Arshad , Farzana Siddique , Pedro Fonte","doi":"10.1016/j.ijpharm.2024.124919","DOIUrl":null,"url":null,"abstract":"<div><div>Chemotherapy in the management of cancer is constrained by limitations like off-target effects, poor bioavailability, and dose-dependent toxicity. Nutraceuticals have been explored as an innovative strategy to overcome chemotherapy drawbacks.However, the clinical utility of nutraceuticals is restricted due to their complex structures, less water solubility, reduced stability, decreased bioavailability and more obstacles in the gastrointestinal tract. Nanonutraceuticals are nanosized nutraceutical particles having enhanced solubility, improved bioavailability, stability, and targeted delivery to specific cells. Nutraceuticals can be co-delivered with other chemotherapeutic drugs in nanocarriers to elicit synergistic effects. The targeting of nutraceuticals against cancer cells can be enabled by coupling ligands with the nanocarriers, which direct to the overexpressed receptors found at the surface of the cancer cells. Transitioning a nanonutraceutical from pre-clinical research to clinical trials is a pivotal step. This focus on advancing their application holds great potential for impacting clinical research and improving the treatment landscape for cancer patients. This review focuses on the role of nutraceuticals for cancer treatment, various nanocarriers for the efficient delivery of nutraceuticals along with co-administration of nutraceuticals with chemotherapeutic drugs using nanocarriers. Also, emphasize the targeting of ligands coupled nanocarriers to the cancer cells along with patents and clinical trials for nanonutraceuticals.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124919"},"PeriodicalIF":5.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378517324011530","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Chemotherapy in the management of cancer is constrained by limitations like off-target effects, poor bioavailability, and dose-dependent toxicity. Nutraceuticals have been explored as an innovative strategy to overcome chemotherapy drawbacks. However, the clinical utility of nutraceuticals is restricted due to their complex structures, less water solubility, reduced stability, decreased bioavailability and more obstacles in the gastrointestinal tract. Nanonutraceuticals are nanosized nutraceutical particles having enhanced solubility, improved bioavailability, stability, and targeted delivery to specific cells. Nutraceuticals can be co-delivered with other chemotherapeutic drugs in nanocarriers to elicit synergistic effects. The targeting of nutraceuticals against cancer cells can be enabled by coupling ligands with the nanocarriers, which direct to the overexpressed receptors found at the surface of the cancer cells. Transitioning a nanonutraceutical from pre-clinical research to clinical trials is a pivotal step. This focus on advancing their application holds great potential for impacting clinical research and improving the treatment landscape for cancer patients. This review focuses on the role of nutraceuticals for cancer treatment, various nanocarriers for the efficient delivery of nutraceuticals along with co-administration of nutraceuticals with chemotherapeutic drugs using nanocarriers. Also, emphasize the targeting of ligands coupled nanocarriers to the cancer cells along with patents and clinical trials for nanonutraceuticals.

Abstract Image

查看原文本刊更多论文

改变癌症治疗：纳米保健品的潜力。

化疗在癌症治疗中受到脱靶效应、生物利用率低和剂量依赖性毒性等限制。然而，由于营养保健品结构复杂、水溶性较差、稳定性较差、生物利用度较低以及在胃肠道中存在较多障碍，其临床应用受到限制。纳米营养保健品是一种纳米级营养保健品颗粒，具有更高的溶解度、生物利用度和稳定性，并能定向输送到特定细胞。营养保健品可与纳米载体中的其他化疗药物联合给药，以产生协同效应。通过将配体与纳米载体耦合，可使营养保健品靶向作用于癌细胞，从而直接作用于癌细胞表面过度表达的受体。纳米保健品从临床前研究过渡到临床试验是关键的一步。将重点放在推进纳米药物的应用上，对影响临床研究和改善癌症患者的治疗前景具有巨大潜力。本综述重点介绍了营养保健品在癌症治疗中的作用、用于有效递送营养保健品的各种纳米载体，以及使用纳米载体将营养保健品与化疗药物联合给药。此外，还强调了配体耦合纳米载体对癌细胞的靶向作用，以及纳米保健品的专利和临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Pharmaceutics 医学-药学

CiteScore

10.70

自引率

8.60%

发文量

951

审稿时长

72 days

期刊介绍： The International Journal of Pharmaceutics is the third most cited journal in the "Pharmacy & Pharmacology" category out of 366 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.